Dr. Karen L. Reckamp on Germline Mutations and Onset of Lung Adenocarcinoma in Smokers and Nonsmokers
Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope, about the link between several gene mutations and lung cancer in smokers vs nonsmokers.
Cancer Network spoke with Anna F.
Cancer Network spoke with Suresh S. Ramalingam, MD, of Emory University, about pemetrexed, bevacizumab, or both for advanced non-squamous NSCLC.
Cancer Network spoke with Taofeek Kunle Owonikoko, MD, PhD, of Emory University, about talazoparib for patients with HRRD-positive stage IV squamous cell lung cancer.
Cancer Network spoke with Kathryn Cecilia Arbour, MD, of Memorial Sloan-Kettering Cancer Center, about the most recent research on checkpoint inhibitors in oncology.
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.
In this video, Shirish M. Gadgeel, MD, of Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC.
Cancer Network spoke with Steven H. Lin, MD, PhD, of MD Anderson Cancer Center, on the findings of a phase II trial of atezolizumab plus chemoradiation therapy in locally advanced non-small-cell lung cancer.
Cancer Network spoke with Nathan A. Pennell, MD, PhD, of Cleveland Clinic at ASCO 2019 regarding current use of and barriers to molecular testing in NSCLC.
Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope at ASCO 2019 about data on emerging MET inhibitors in the treatment of lung cancer patients.